ADMANasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31

ADMA BIOLOGICS, INC.

Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 5, 2026

$11.07+0.39 (+3.65%)

Close on Oct 19, 2026

Market cap: $2.55B
P/E (TTM): 15.8
Dividend yield: –

Debt

Borrowings on the balance sheet, Jun 30, 2026

Total debt

$196.59M

$3.75M due within a year

Net debt

$60.57M

After $136.02M of cash

Implied interest rate

9.84%

FY2025 interest ÷ average debt

Interest coverage

26.9×

FY2025 operating income ÷ interest

Total debt by fiscal year

Long-term plus current debt, USD

Bond issues

Individual notes and bonds outstanding

Bond-level data is not connected yet

Coupon, maturity and amount of each note will come from the debt footnote in Adma Biologics's annual report. Trading prices and yields need FINRA TRACE data.

Where these numbers come from

Parsed from the XBRL in Adma Biologics's annual and quarterly filings with the SEC
Fourth quarters derived from the annual report minus nine months
Every figure in the statements links to its source filing

Against peers

Trailing twelve months. Peers are matched on business description, industry and size. Ticks are peers, the dot is ADMA.

Revenue growth8.0% · median 19.6%

Gross margin64.7% · median 48.4%

Operating margin43.8% · median 11.4%

Net margin33.0% · median 5.3%

Company	Revenue	Growth
RGEN	$785.10M	+16.5%
ADMA	$512.28M	+8.0%
KRYS	$440.48M	+22.6%
IOVA	$324.97M	+34.5%
KMDA	$180.46M	+12.1%
ALVO	–	–

Company

Next earnings (est.): Nov 4, 2026, during market hours
Exchange: Nasdaq
Industry: Biological Products, (No Diagnostic Substances)
Fiscal year ends: December 31
Employees: 647
Held by institutions: 91.8%
Auditor: KPMG LLP
SEC CIK: 1368514

Advertisement
300 × 250